4597 — Solasia Pharma KK Income Statement
0.000.00%
Last trade - 00:00Annual income statement for Solasia Pharma KK, fiscal year end - December 31st, JPY millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Yuho | Yuho | Yuho | Yuho | Yuho |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 559 | 1,092 | 617 | 316 | 429 |
| Cost of Revenue | |||||
| Gross Profit | 374 | 662 | 337 | 185 | 208 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 2,978 | 3,562 | 1,756 | 2,267 | 1,290 |
| Operating Profit | -2,419 | -2,470 | -1,139 | -1,951 | -861 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -2,442 | -2,492 | -1,135 | -1,961 | -876 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -2,477 | -2,548 | -1,113 | -1,942 | -876 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -2,477 | -2,548 | -1,113 | -1,942 | -876 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -2,478 | -2,548 | -1,112 | -1,941 | -876 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -19 | -18.1 | -6.61 | -9.77 | -3.69 |
| Dividends per Share |